SHINGLES DISEASE PROCESS AND VACCINATION FOR PHARMACISTS Final Examination Questions Select the best answer for each question and then proceed to EliteLearning.com/Book to complete your final examination.
86. After initial exposure, the varicella zoster virus enters an incu- bation period of approximately _________ , while it replicates in the body.
92. Shingrix is a recombinant, adjuvanted vaccine for intra- muscular injection and is FDA approved for use in patients _____________ years of age and older.
a. 4 days. b. 7 days. c. 2 weeks. d. 4 weeks.
a. 40. b. 60. c. 55. d. 50.
87. Herpes zoster, commonly known as shingles, affects approx- imately one out of every _____________ Americans in their lifetime. a. Three. b. Two. c. Five. d. 10. 88. Around _______ of patients experience pain before develop- ing the shingles rash, known as prodromal pain.
93. The Shingrix pre-approval study that assessed vaccine ef- ficacy in subjects ages 50 and older found that two doses of Shingrix resulted in a significant reduction in the risk of developing shingles by _____________ when compared with placebo. a. 51 percent. b. 97.2 percent. c. 89 percent. d. 62 percent. 94. If not used immediately after reconstitution, Shingrix can be stored under refrigeration and used within __________.
a. 25%. b. 50%. c. 75%. d. 85%. 89. The most common complication of shingles is:
a. 60 minutes. b. 30 minutes. c. 12 hours. d. 6 hours.
a. Ramsey-Hunt syndrome. b. Post-herpetic neuralgia. c. Bacterial skin infections. d. Blindness. 90. In treating shingles, acyclovir is commonly administered at a dose of:
95. If the second dose of Shingrix is administered less than four weeks after the first dose, the Advisory Committee on Immu - nization Practices (ACIP) recommends: a. No further action. b. Restarting the series. c. Repeating the second dose. d. Drawing a titer to assess efficacy.
a. 500 mg three times daily for 7 days. b. 1000 mg five times daily for 10 days. c. 800 mg five times daily for 7 days. d. 800 mg three times daily for 10 days.
91. Shingrix must be stored properly to ensure viability of the virus component of the vaccine. It must be stored between:
a. -58°F and +5°F. b. 36°F and 46°F. c. 0°F and 25°F. d. 30°F and 50°F.
Course Code: RPUS01SH
EliteLearning.com/Pharmacy
Book Code: RPUS3024
Page 137
Powered by FlippingBook